Rye Staging System

(redirected from Lymphocyte-depleted)

Rye Staging System

A system for staging Hodgkin's disease delineated in 1966, which divided it into 4 distinct clinicopathological categories, based on data provided by the then popular method of lymphangiography. Cf Ann Arbor classification, Cotswolds classification.
Rye Classification–Hodgkin's disease
Lymphocytic predominant 10% of cases, more common in young adult ♂, usually early/low-stage disease without 'B' symptoms, 5-year survival: 90%
Nodular sclerosing 40%; more common in young adult ♀, usually early and low-stage disease with or without 'B' symptoms, 5-year survival: 70%
Mixed cellularity 40%; more common in young adult ♂, often stage II-III disease with or without 'B' symptoms, 5-year survival: 50%
Lymphocyte-depleted 10%; more common in older adult ?, usually stage III-IV disease with or without 'B' symptoms, 5-year survival, 30%
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
(CHL = classic Hodgkin CHL-NS = nodular sclerosis CHL; CHL-MC = mixed-cellularity CHL; CHL-LR = lymphocyte-rich CHL; CHL-LD = lymphocyte-depleted CHL; NLPHL = nodular lymphocyte-predominant CHL.)
They also found in the lymphocyte-depleted mice that intravenously injected lymphocytes swiftly adhere to HEVs and penetrate the HEV wall (Fig.
It includes a 10-year epidemiology forecast for the diagnosed incident cases of HL, segmented by age, sex, and clinical stage at diagnosis, and types (classical HL and nodular lymphocyte predominant HL, with classical HL further segmented into subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) in these markets.
Generally, there are four subtypes of CHL; nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. These subtypes may differ in the clinicopathological aspects, however, the immunophenotype of the tumor cells remain the same.
Classical Hodgkin's lymphoma is further sub-typed into nodular sclerosis, lymphocyte-rich, mixed cellularity and lymphocyte-depleted subtypes (1, 5).
Rooney et al., "[gamma][delta] T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors," Bone Marrow Transplantation, vol.
Because of her symptoms of fever and night sweats and the histologic findings demonstrating HD, lymphocyte-depleted type, the patient received cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone chemotherapy for the next 6 months without any serious adverse effects.
Ber-H2 reacts with approximately 95% of cases of anaplastic large cell lymphoma (ALCL) and Reed-Sternberg cells and variants in about 90% of cases of nodular sclerosis, mixed cellularity, and lymphocyte-depleted Hodgkin lymphoma.[1,4-9] However, Ber-H2 reacts with Reed-Sternberg cells in only about 5% of cases of nodular lymphocyte predominance Hodgkin lymphoma.[10] Ber-H2 positivity may also be seen in other types of B-cell and T-cell non-Hodgkin lymphoma and plasma cell dyscrasias.

Full browser ?